Evotec SE

XTRA:EVT 주식 리포트

시가총액: €845.0m

Evotec 경영진

경영진 기준 점검 1/4

현재 CEO에 대한 정보가 충분하지 않습니다.

핵심 정보

Christian Wojczewski

최고경영자

€4.5m

총 보수

CEO 급여 비율19.90%
CEO 재임 기간1.9yrs
CEO 지분 보유율n/a
경영진 평균 재임 기간1.2yrs
이사회 평균 재임 기간4.5yrs

최근 경영진 업데이트

Recent updates

내러티브 업데이트 • Jun 06

EVT: AI And Royalty Pipeline Will Support Future Earnings Upside

Analysts have slightly adjusted their outlook on Evotec, keeping the fair value estimate steady at €10.00 while fine tuning assumptions around discount rate, revenue growth, profit margin, and future P/E to reflect updated expectations for the business. What's in the News Evotec appointed Rui Wang as Executive Vice President, Head of Global In Silico and AI, to lead the integration of computational science and data driven decision making across its R&D operations, positioning AI and in silico capabilities as key parts of the company’s commercial offering.
내러티브 업데이트 • May 23

EVT: Future Milestone And Royalty Stream Will Support Earnings Upside

Analysts have trimmed their price target on Evotec from €10.40 to €10.00, citing updated assumptions for revenue growth, profit margins, discount rate and future P/E that now sit slightly below prior estimates but remain within a similar range. What's in the News Evotec and Almirall nominated a small molecule preclinical development candidate for immune mediated inflammatory skin diseases, using Evotec’s AI/ML supported discovery and preclinical platforms, with potential success based milestones of up to €230 million per program plus high single digit royalties on net sales (Key Developments).
내러티브 업데이트 • May 04

EVT: Activist Proposals And 2026 Guidance Will Drive Future Upside

Analysts have slightly reduced their price target on Evotec to €6.83 from €6.92, reflecting updated views on discount rates, revenue growth, profit margins and future P/E assumptions. What's in the News Evotec expects full year 2026 group revenues of approximately €700 million to €780 million, with constant currency guidance of €730 million to €810 million (company guidance).
내러티브 업데이트 • Apr 19

EVT: Higher Revenue Guidance Will Be Undermined By Weaker Profitability Assumptions

Analysts have adjusted their price target on Evotec to €4.40. The change is framed by updated views on discount rates, revenue growth assumptions, profit margins and a higher future P/E multiple.
내러티브 업데이트 • Apr 05

EVT: 2025 And 2026 Revenue Guidance Will Support Future Upside

Analysts have reduced their price target on Evotec by €1.80, citing updated views on fair value, discount rate, revenue growth and profit margin assumptions, and also reflecting a revised future P/E outlook. What's in the News Evotec issued new earnings guidance for full-year 2026, targeting group revenues of about €700-780 million or €730-810 million at constant exchange rates (Key Developments).
내러티브 업데이트 • Mar 21

EVT: Earnings Outlook Will Balance Higher Guidance With Tighter Profit Assumptions

Analysts have reduced their Evotec price targets from €6.00 to €4.40 as they apply a higher discount rate, assume slower revenue growth and lower profit margins, and factor in a slightly higher future P/E of 24.33x. What's in the News Evotec raised its full-year 2025 earnings guidance, now expecting group revenues of approximately €788 million at the high end of its €760 to €800 million range, or €811 million at constant exchange rates (Key Developments) The company confirmed new earnings guidance for full-year 2026, with group revenues expected in a range of approximately €700 to €780 million, or €730 to €810 million at constant exchange rates (Key Developments) Valuation Changes Fair Value: reduced from €6.00 to €4.40 per share, reflecting a lower implied valuation level.
내러티브 업데이트 • Mar 07

EVT: Future Milestone And Royalty Stream Will Drive Earnings Upside

Analysts have trimmed their price target on Evotec to €10.40. This reflects updated assumptions for revenue growth, profit margins and a higher future P/E multiple.
내러티브 업데이트 • Feb 20

EVT: Kidney Disease Milestone Prospects Will Support Future Upside

Analysts have made only a very small adjustment to their Evotec price target, keeping it effectively unchanged at about €8.72. Updated assumptions for discount rate, revenue growth, profit margin and future P/E remain closely aligned with prior estimates.
내러티브 업데이트 • Feb 06

EVT: Kidney Disease Milestones And Novo Stake Sale Will Support Future Upside

Analysts have adjusted their fair value estimate for Evotec from €8.46 to approximately €8.72, citing updated views on discount rates, revenue growth, profit margins and future P/E assumptions as the main factors behind the latest price target revision. What's in the News Novo Holdings is reportedly planning to sell up to 9.4 million Evotec shares, equal to about 5% of Evotec's share capital, after previously holding 14.9 million shares or 8.4% of the company (Key Developments).
내러티브 업데이트 • Jan 22

EVT: Milestone Progress And Share Buybacks Will Support Future Upside

Analysts have slightly adjusted their price target on Evotec to reflect updated assumptions around discount rate, revenue growth, profit margin and future P/E. The fair value estimate remains steady at €8.46.
내러티브 업데이트 • Jan 07

EVT: Milestone Payment And Buyback Will Support Future Upside

Analysts have kept their fair value estimate for Evotec steady at €8.46, with only marginal tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions, reflecting a largely unchanged fundamental view. What's in the News Novo Holdings is reportedly planning to sell up to 9.4 million Evotec shares, around 5% of the company, after previously holding 14.9 million shares or 8.4% of the capital.
내러티브 업데이트 • Dec 17

EVT: Future Milestone And Royalty Stream Will Drive Earnings Upside

Analysts have trimmed their price target on Evotec from €12.00 to €10.40. The revision reflects a higher perceived discount rate despite stronger expectations for revenue growth and profit margins.
내러티브 업데이트 • Dec 03

EVT: Share Buybacks And Milestone Payment Will Support Future Upside

Analysts have lowered their price target on Evotec from approximately $9.47 to about $8.46. They cited a higher perceived discount rate and slightly softer long term revenue growth expectations, partially offset by improved profit margin forecasts and a more moderate future price to earnings multiple.
내러티브 업데이트 • Aug 21

Large Pharma Partnerships And AI Platforms Will Open New Markets

The notable reduction in Evotec’s Analyst Price Target reflects a lower expected future P/E and a slight moderation in revenue growth forecasts, leading to a new consensus fair value of €9.43. What's in the News Evotec lowered FY2025 revenue guidance to EUR 760–800 million (previously EUR 840–880 million) due to changes in revenue mix and higher-than-expected cost savings; technology licensing is expected to contribute more, while Shared R&D faces market challenges.
User avatar
새로운 내러티브 • Apr 30

Pharmaceutical Collaborations And Cost Savings Will Drive Excellence

Strengthened partnerships with major pharma companies and a focus on biologics manufacturing are expected to boost Evotec's revenue and earnings.
분석 기사 • Nov 10

Evotec SE (ETR:EVT) Just Reported Earnings, And Analysts Cut Their Target Price

Evotec SE ( ETR:EVT ) missed earnings with its latest quarterly results, disappointing overly-optimistic forecasters...
분석 기사 • Nov 05

A Piece Of The Puzzle Missing From Evotec SE's (ETR:EVT) 32% Share Price Climb

Those holding Evotec SE ( ETR:EVT ) shares would be relieved that the share price has rebounded 32% in the last thirty...
분석 기사 • Aug 17

Evotec SE (ETR:EVT) Just Reported Earnings, And Analysts Cut Their Target Price

Investors in Evotec SE ( ETR:EVT ) had a good week, as its shares rose 4.5% to close at €5.80 following the release of...
분석 기사 • Aug 08

Evotec SE (ETR:EVT) Stock's 45% Dive Might Signal An Opportunity But It Requires Some Scrutiny

The Evotec SE ( ETR:EVT ) share price has fared very poorly over the last month, falling by a substantial 45%. The...
분석 기사 • Aug 03

We Think Evotec (ETR:EVT) Has A Fair Chunk Of Debt

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
분석 기사 • Apr 10

Investors Aren't Entirely Convinced By Evotec SE's (ETR:EVT) Revenues

You may think that with a price-to-sales (or "P/S") ratio of 3.1x Evotec SE ( ETR:EVT ) is a stock worth checking out...
분석 기사 • Mar 05

These 4 Measures Indicate That Evotec (ETR:EVT) Is Using Debt Reasonably Well

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
분석 기사 • Jan 09

A Piece Of The Puzzle Missing From Evotec SE's (ETR:EVT) Share Price

With a median price-to-sales (or "P/S") ratio of close to 3.9x in the Life Sciences industry in Germany, you could be...

CEO 보수 분석

Christian Wojczewski의 보수는 Evotec의 수익에 비해 어떻게 변했나요?
날짜총 보수급여회사 수익
Mar 31 2026n/an/a

-€194m

Dec 31 2025€5m€900k

-€104m

Sep 30 2025n/an/a

-€159m

Jun 30 2025n/an/a

-€156m

Mar 31 2025n/an/a

-€207m

Dec 31 2024€1m€450k

-€196m

보상 대 시장: Christian의 총 보수(USD5.22M)는 German 시장에서 비슷한 규모 기업의 평균(USD1.10M)보다 높습니다.

보상과 수익: Christian의 보상은 회사가 적자임에도 증가했습니다.

CEO

Christian Wojczewski (53 yo)

1.9yrs
재임 기간
€4,523,000
보수

Dr. Christian Wojczewski is CEO & Chairperson of the Management Board of Evotec SE. Dr. Wojczewski was CEO & Management Board Member of Evotec SE from July 1, 2024 He joined the Evotec SE on July 1, 2024....

리더십 팀

이름직위재임 기간보수지분
Christian Wojczewski
CEO & Chairperson of the Management Board1.9yrs€4.52m데이터 없음
Cord Dohrmann
Chief Scientific Officer & Member of Management Board15.8yrs€1.49m데이터 없음
Aurelie Dalbiez
Chief People Officer & Member of Management Board2yrs€1.69m데이터 없음
Claire Hinshelwood
CFO & Member of Management Boardless than a year데이터 없음데이터 없음
Ingrid Mller
COO & Member of Management Boardless than a year데이터 없음데이터 없음
Sarah Fakih
Executive VPless than a year데이터 없음데이터 없음
Christian Dargel
EVP Global Head of Legal & Complianceno data데이터 없음데이터 없음
Ian Hunneyball
Senior Vice President of Programme Management & Clinical Operationsno data€116.00k데이터 없음
David Hallet
Executive Vice Presidentno data데이터 없음데이터 없음
Uwe Andag
EVP Head of Metabolic Diseasesno data데이터 없음데이터 없음
Christiane Honisch
SVP Head of Diagnosticsno data데이터 없음데이터 없음
Claudia Karnbach
Global Head & Executive VP of Partnering Excellence & Operationsno data데이터 없음데이터 없음
1.2yrs
평균 재임 기간
54.5yo
평균 나이

경험이 풍부한 관리: EVT의 경영진은 경험이 부족한 것으로 간주됩니다(평균 재임 1.2 년) — 신규 팀일 수 있습니다.

이사회 구성원

이름직위재임 기간보수지분
Wesley Wheeler
Independent Member of the Supervisory Board2yrs€80.00k데이터 없음
Roland Sackers
Independent Vice Chairperson of the Supervisory Board7yrs€150.00k데이터 없음
Iris Low-Friedrich
Independent Chairperson of the Supervisory Board12yrs€155.00k데이터 없음
Duncan McHale
Independent Member of the Supervisory Board2yrs€80.00k데이터 없음
Camilla Languille
Member of the Supervisory Board4yrs€95.00k데이터 없음
Constanze Ulmer-Eilfort
Independent Member of Supervisory Board5yrs€110.00k데이터 없음
4.5yrs
평균 재임 기간
61.5yo
평균 나이

경험이 풍부한 이사회: EVT의 이사회는 경험이 있음으로 간주됩니다(평균 재임 4.5 년).

기업 분석 및 재무 데이터 상태

데이터최종 업데이트 (UTC 시간)
기업 분석2026/06/09 09:25
종가2026/06/09 00:00
수익2026/03/31
연간 수익2025/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지데이터기간미국 소스 예시 *
기업 재무제표10년
  • 손익계산서
  • 현금흐름표
  • 대차대조표
분석가 컨센서스 추정치+3년
  • 재무 예측
  • 분석가 목표주가
시장 가격30년
  • 주가
  • 배당, 분할 및 기타 조치
지분 구조10년
  • 주요 주주
  • 내부자 거래
경영진10년
  • 리더십 팀
  • 이사회
주요 개발10년
  • 회사 공시

* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Evotec SE는 23명의 분석가가 다루고 있습니다. 이 중 10명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가기관
Christian EhmannBerenberg
Michael RyskinBofA Global Research
Peter VerdultCitigroup Inc